Equities analysts expect that Icon Plc (NASDAQ:ICLR) will post earnings of $1.31 per share for the current quarter, Zacks reports. Eight analysts have made estimates for Icon Plc’s earnings, with estimates ranging from $1.27 to $1.37. Icon Plc posted earnings per share of $1.19 in the same quarter last year, which indicates a positive year-over-year growth rate of 10.1%. The firm is expected to announce its next earnings report on Thursday, October 19th.

According to Zacks, analysts expect that Icon Plc will report full year earnings of $5.31 per share for the current fiscal year, with EPS estimates ranging from $5.27 to $5.37. For the next fiscal year, analysts forecast that the firm will post earnings of $5.91 per share, with EPS estimates ranging from $5.80 to $6.06. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Icon Plc.

Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.30 by $0.01. The firm had revenue of $431 million for the quarter, compared to analyst estimates of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. Icon Plc’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $1.14 earnings per share.

A number of equities analysts have recently issued reports on the company. KeyCorp reissued an “overweight” rating on shares of Icon Plc in a research note on Monday, July 31st. SunTrust Banks, Inc. raised Icon Plc from a “hold” rating to a “buy” rating and increased their target price for the stock from $93.00 to $126.00 in a research note on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating on shares of Icon Plc in a research note on Sunday, July 30th. Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a research note on Friday, July 28th. Finally, Mizuho increased their target price on Icon Plc from $104.00 to $108.00 and gave the stock a “neutral” rating in a research note on Thursday, July 27th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $108.38.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Icon Plc (NASDAQ:ICLR) Will Post Earnings of $1.31 Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/zacks-brokerages-expect-icon-plc-nasdaqiclr-will-post-earnings-of-1-31-per-share.html.

Large investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its stake in shares of Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares during the period. Meritage Portfolio Management boosted its stake in shares of Icon Plc by 0.8% in the first quarter. Meritage Portfolio Management now owns 63,907 shares of the medical research company’s stock worth $5,095,000 after buying an additional 525 shares during the period. Duff & Phelps Investment Management Co. boosted its stake in shares of Icon Plc by 16.9% in the first quarter. Duff & Phelps Investment Management Co. now owns 145,652 shares of the medical research company’s stock worth $11,611,000 after buying an additional 21,037 shares during the period. Somerset Trust Co boosted its stake in shares of Icon Plc by 0.4% in the first quarter. Somerset Trust Co now owns 5,638 shares of the medical research company’s stock worth $449,000 after buying an additional 24 shares during the period. Finally, Farmers & Merchants Investments Inc. boosted its stake in shares of Icon Plc by 11.5% in the first quarter. Farmers & Merchants Investments Inc. now owns 51,236 shares of the medical research company’s stock worth $4,085,000 after buying an additional 5,269 shares during the period. Institutional investors and hedge funds own 92.55% of the company’s stock.

Icon Plc (NASDAQ:ICLR) traded up 0.82% during mid-day trading on Tuesday, reaching $105.42. The company had a trading volume of 115,794 shares. The company has a market capitalization of $5.70 billion, a price-to-earnings ratio of 21.38 and a beta of 0.60. The firm’s 50 day moving average price is $98.45 and its 200-day moving average price is $87.84. Icon Plc has a 12 month low of $73.76 and a 12 month high of $109.32.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon Plc (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.